Form 4: Bicycle Therapeutics CEO Sells Shares
Insider Transaction Filing
Bicycle Therapeutics CEO Kevin Lee reported the sale of 7,683 ordinary shares, primarily to cover tax withholding obligations.
Summary
- Kevin Lee, Chief Executive Officer and Director of Bicycle Therapeutics PLC, reported transactions involving the sale of ordinary shares.
- On April 2, 2026, 5,967 shares were sold at a weighted average price of $4.91, with individual sales ranging from $4.88 to $4.98.
- On April 6, 2026, an additional 1,716 shares were sold at a weighted average price of $5.05, with individual sales ranging from $5.03 to $5.05.
- These sales were primarily to cover statutory tax withholding obligations related to the vesting and settlement of Restricted Stock Units (RSUs), as mandated by the award agreement.
- Following these transactions, Kevin Lee beneficially owns 611,313 ordinary shares directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as the reported share sales are attributed to mandatory tax withholding obligations rather than a reflection of the executive's confidence in the company's future prospects.
Negatives
- CEO Kevin Lee sold a total of 7,683 ordinary shares.
- The sales occurred at prices between $4.88 and $5.05 per share.
Future Outlook
No specific future outlook or guidance was provided in this filing.
Industry Context
StockSavvy.ai notes that Form 4 filings are routine disclosures for executive stock transactions. The primary driver for these sales appears to be tax obligations related to RSU vesting, which is a common occurrence for executives in publicly traded companies, rather than a discretionary decision to divest shares based on company performance.
Stakeholder Impact
- Shareholders: The sale of shares by the CEO, even if for tax purposes, may be perceived by some shareholders as a reduction in insider ownership, though the context of tax withholding mitigates this concern.
- Employees: The transaction relates to executive compensation and does not directly impact other employees.
- Creditors: No direct impact on creditors is indicated by this filing.
- Suppliers: No direct impact on suppliers is indicated by this filing.
- Customers: No direct impact on customers is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 04/02/2026 | Date of initial share sale transaction. |
| 04/06/2026 | Date of subsequent share sale transaction. |
Keywords
Bicycle Therapeutics, BCYC, Form 4, Insider Trading, Share Sale, CEO, Kevin Lee, RSU Vesting, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.